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To evaluate safety, acceptability and pilot efficacy of transcutaneous low frequency 
tibial nerve stimulation (TNS) using a novel home-based neuromodulation device.  
 
Patients and methods  
In this single centre pilot study, 48 patients with OAB (24 with neurogenic and 24 
with idiopathic OAB) were randomized to use a self-applicating ambulatory skin-
adhering device stimulating transcutaneously the tibial nerve behind the medial 
malleoulus for 30 minutes, either once daily or once weekly, for 12-weeks. Changes 
in OAB symptoms and quality of life (QoL) were measured at baseline, weeks 4, 8, 
and 12 using validated scoring instruments (ICIQ-OAB and ICIQ-LUTSqol), 3-day 
bladder diary data and a Global Response Assessment (GRA) at week 12. Compliance 
was assessed through weekly phone calls and a usage diary. 
  
Results  
Thirty-four patients completed the study (idiopathic OAB n=15, neurogenic OAB 
n=19). No significant adverse effects were noted. Patients found using the device 
acceptable, rating the treatment as easy to use, comfortable, and were very satisfied 
with this treatment modality. Eighteen patients (53%) reported a moderate or marked 
improvement in symptoms according to the GRA. Between baseline and week -12, 
ICIQ-OAB part A sub-scores improved from mean (SD) 9.3 (2.5) to 7.5 (3.1), and 
from 9.1 (1.9) to 5.9 (1.7) in the daily and the weekly arms, respectively. ICIQ-OAB 
part B sub-scores improved from 29.6 (8.1) to 25.6 (9.5) (p=0.2) in the daily arm, and 
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from 29.7 (5.9) to 19.1 (8.5) in the weekly arm. ICIQ-LUTSqol part A sub-scores 
improved from mean (SD) 51 (12.8) to 44.2 (13.1) and 44.9 (9.0) to 35.9 (8.8) in the 
daily and the weekly arms, respectively. ICIQ-LUTSqol part B subscores improved 
from 130.3 (43.7) to 105.5 (57.8) in the daily arm, and from 102.1 (40.1) to 63.9 
(42.8) in the weekly arm.  3-Day bladder diary improvements were also noted as 24 
hour urinary frequency improved from 11.5 at baseline to 8.8 at week 12 in the daily 
arm in both arms combined. Improvements were observed in patients with both 
idiopathic and neurogenic OAB.   
 
Conclusion 
This novel ambulatory transcutaneous TNS device is safe and acceptable for use in 
patients reporting OAB symptoms for home-based neuromodulation.  Preliminary 
evidence suggests efficacy, however this needs to be confirmed in a larger study.  
 
 



















Tibial nerve stimulation (TNS) has emerged as an effective alternative for the 
management of the overactive bladder (OAB). Consisting of intermittent electrical 
stimulation of the tibial nerve, the efficacy of this treatment has been demonstrated in 
several studies, including a multicentric, double-blind, randomised sham-controlled 
study of patients with idiopathic OAB [1, 2].  More recently, the treatment has 
appeared in National Institute for Health and Care Excellence (NICE) guidance as a 
second-line option for the management of female urinary incontinence [3] [4].  
 
In clinical practice, the tibial nerve is most often stimulated percutaneously (PTNS) 
by inserting a needle, however this entails regular visits to an outpatient clinic over 8 
to 12 weeks.   Being resource intense in terms of time, financial and staff 
commitments, this treatment is often not a feasible option from the point of view of 
health care delivery. Moreover, the treatment may not be an option for patients 
requiring to travel long distances, those having disabilities requiring special transport 
arrangements and those unable to commit to a 3 month block of treatment.  Adverse 
effects such as pain, bruising, tingling or bleeding at the insertion site is reported in 
upto 8% of patients, and this may limit acceptability of this treatment [5].  Perhaps 
reflecting these limitations, the results of a long-term follow up study of patients 
undergoing PTNS treatment showed poor compliance to PTNS over time [6].   
 
Non-invasive alternatives, whereby the tibial nerve is stimulated transcutaneously 
(TTNS) at a home-based setting, have therefore been explored [7]. Early results have 
been promising, demonstrating improvements in OAB symptom scores and 
urodynamic parameters [7, 8].  So far, these studies have been using a TENS 
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(transcutaneous electrical nerve stimulation) machine for stimulating the tibial nerve 
at frequencies between 10 to 40 Hz, which can be administered by the patient at home 
using pre-determined stimulation settings [9].  Using a TENS machine however 
restricts the mobility of patients during the time that the nerve is being stimulated.  
Recently, a self-applicating skin-adhering ambulatory device, known as geko™ 
(Firstkind Limited, Buckinghamshire, UK) (figure. 1) has been developed and has 
received a CE mark for the prevention of deep vein thrombosis through chronic 
popliteal fossa stimulation, with no reported safety concerns [10]. This device has 
recently been piloted in a study exploring outcomes in a cohort of patients reporting 
faecal incontinence, with promising results [11].   Whether this device has a role in 
managing urinary incontinence is uncertain, and therefore the aim of this study was to 
evaluate the safety, acceptability and pilot efficacy of the gekoTM device for 
transcutaneous stimulation of the tibial nerve in patients with OAB.    
 
Materials and methods 
 
Patients 
Patients with OAB symptoms attending a tertiary centre teaching hospital who found 
conservative first-line management options either ineffective or intolerable were 
enrolled in this randomised open label parallel-arm 12 week pilot trial of once daily 
versus once weekly 30 minute stimulation of the tibial nerve.  
  
All participants provided written informed consent prior to enrolment. Patient 
eligibility was based on meeting the criteria for an overactive bladder, defined by the 
International Continence  Society as an average urinary frequency ≥ 8 voids and  1 
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urgency episode (with or without incontinence) per 24 hours [12]. Patients with 
neurological disease reporting OAB symptoms were enrolled if their Expanded 
Disability Status Scale (EDSS) score was ≤ 6.5. Exclusion criteria included use of 
botulinum toxin A treatment within the previous year or neuromodulation (TNS or 
sacral neuromodulation), patients with sensory loss in the gaitor region (cutaneous 
sensation to nociception was assessed in the lower limb), presence of urinary tract 
infection or any other documented LUT pathology. Participants on antimuscarinic 
medications for OAB went through a 2-week run-in washout period during which 
time medications were discontinued. 
 
Intervention 
Patients were assigned to one of two treatment arms using the sealed envelope 
stratified randomisation service 
(https://www.sealedenvelope.com/randomisation/internet/). A dedicated member of 
the study team recruited participants and collected baseline and follow-up data. It was 
not deemed possible to include a control group as TTNS relies upon supra-sensory 




Patients were provided an antiseptic wipe to clean the area and a pad for simple skin 
exfoliation.  They were trained to use the device and attach over the tibial nerve by a 
self-adhesive gel 1 cm behind the medial malleolus in a vertical position (figure 1).  
The area of stimulation was up to 5 cm cephalad to the medial malleolus.  Patients 
were asked to apply the device over the same ankle if possible. 
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The device has default stimulation parameters delivering a constant 27mA current, at 
a frequency of 1Hz. The pulse width was increased between a range of 7 settings 
(between 70 and 560µs) and was sequentially increased depending upon the 
maximum tolerable sensory and best sensory-motor response (toe flexion and fanning, 
tingling sensation).  Patients were encouraged to use the device at home and to carry 
on with daily activities with no restriction to ambulation, however bathing and driving 




The primary objective of the study was to assess safety and acceptability of the device 
and this was measured through a customized compliance diary in which entries could 
be made by patients to record compliance as well as their experiences whilst using the 
device and any adverse effects.   Additionally, a member of the research team made 
weekly phone calls to ensure patients were applying correctly and achieving adequate 
sensory-motor responses during stimulations. 
 
Treatment response was assessed using the Global Response Assessment (GRA) at 
week 12 of treatment, and the International Consultation on Incontinence 
Questionnaires for the overactive bladder and LUTS-related quality of life (ICIQ-
OAB and ICIQ-LUTSqol) at baseline, week 4, 8 and 12.  The GRA was based on a 
similar questionnaire used previously where patients were asked to assess their 
response to treatment using an ordinal scale of 0 to 3, referring to none, mild, 
moderate or marked improvement, respectively [1]. Patients reporting moderate or 
marked improvement were considered to have responded to treatment [1]. The ICIQ-
OAB score is a 6-item questionnaire that assesses OAB symptom severity and bother 
and the ICIQ-LUTSqol score is a 20-item health related quality of life questionnaire. 
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In both questionnaires, part A assesses symptom severity and part B assesses the 
accumulative bother to the patient. Higher scores in each suggests worse symptom 
profiles and negative impact on QoL, respectively. Patients were also asked to 
complete 3-day bladder diaries to capture the mean 24hour urinary frequency 




A feasibility sample size of 48 patients was adopted and no formal power calculation 
was performed as is the convention for pilot studies with no prior data to base a 
sample size on [13]. All data were presented as means with SDs. Paired student t-tests 
were used to provide an estimate of within group responses between baseline and 12 
weeks.  
 
The study received ethics approvals from the Surrey Borders NRES Committee 
London (Ref: 12/LO/1613) and the Medicines and Healthcare Products Regulatory 
Agency (MHRA).  
 
Results 
Forty-eight patients met the eligibility criteria (neurogenic OAB (Multiple Sclerosis, 
MS)) (n=24) and idiopathic OAB (n=24)) and were 1:1 randomised to receive once 
daily (n=24) or once weekly (n=24) treatment. Participants randomized into the daily 
and weekly groups were comparable for age, sex, diagnosis and symptom severity. 
The mean age (range) for the daily and weekly arms were 46.4 (32-73) and 46.9 (20-
81) years, female to male patients 18:6 and 20:4, and the number of patients with 
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incontinence of 20 and 18 in the two respective arms. Thirty-four patients completed 
12-weeks of treatment and the reasons for withdrawing are outlined in Figure 2. 
 
Patient compliance and acceptability  
Compliance for using the device amongst participants randomized to receive daily 
treatment was 90.5% (76 out of the 84 daily applications) compared to 100% amongst 
patients randomized to receive weekly treatment (12 out of the 12 weekly 
applications). The participants throughout the course of treatment noted no significant 
concerns and the responses to the satisfaction survey are shown in table 1. Five 
patients found the electrical stimulation uncomfortable and discontinued treatment 
(Figure 2). There were no significant safety concerns raised during the 12 weeks 
course of treatment. One patient developed mild skin redness at the site of 
stimulation, likely to be due to sensitivity to the adhesive, and was withdrawn from 
the study (Figure 2).  
 
Changes in OAB symptoms 
Eighteen (53%) (daily treatment (n=9), weekly (n=9)) participants reported a 
moderate or significant improvement in symptoms on the GRA. No differences were 
noted between responders and non-responders with regards to age, gender, diagnosis, 
degree of disability (in the neurological group). Sixty-five percent (13/20) of 
neurological patients with OAB and 36% (5/14) of patients with idiopathic OAB 
responded to the  intervention (Table 2). 
 
Improvements were observed in both ICIQ-OAB and ICIQ-LUTSqol scores between 
baseline and over the course of 12 weeks treatment in both the weekly and daily arms 
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(Figure 3). In the daily arm, mean (SD) ICIQ-OAB part A subscores improved 
between baseline and week 12 from 9.3 (2.5) to 7.5 (3.1), and from 9.1 (1.9) to 5.9 
(1.7) in the weekly arm. ICIQ-OAB part B subscores improved from 29.6 (8.1) to 
25.6 (9.5) in the daily arm, and from 29.7 (5.9) to 19.1 (8.5) in the weekly arm 
(Figure 3). 
 
ICIQ-LUTSqol part A subscores improved from 51 (12.8) to 44.2 (13.1) in the daily 
arm and from 44.9 (9.0) to 35.9 (8.8) in the weekly arm. ICIQ-LUTSqol part B 
subscores improved from 130.3 (43.7) to 105.5 (57.8) in the daily arm, and from 
102.1 (40.1) to 63.9 (42.8) in the weekly arm (Table 3).  
 
Improvements were also noted in the 3-day bladder diary mean.   24 hour urinary 
frequency improved from 11.5 at baseline to 8.8 at week 12 in the daily arm in both 







This study evaluates the feasibility of  using  a novel ambulatory device (GekoTM)  for 
transcutaneously stimulating the tibial nerve in patients reporting OAB symptoms. 
Participants largely found the treatment satisfactory, tolerable and convenient to use. 
Compliance was assessed through the use of a diary which provided a written record 
of all the stimulation sessions. Patients receiving the treatment every day were 
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compliant 90% of the time, whereas those receiving weekly treatment were 100% 
compliant.  Being a new indication for the device, patients were contacted on a 
weekly basis to assess safety, and the device was found to be safe to use over the 
ankle with no significant adverse events reported.  These results are in line with 
previous studies where the device was used to stimulate the tibial nerve for managing 
fecal incontinence [11], and over the popliteal fossa for preventing deep venous 
thrombosis [10]. 
 
Several studies have previously demonstrated the efficacy of TTNS for the 
management of OAB.  In an earlier study, Amarenco et al., investigated 
Transcutaneous Electrical Nerve Stimulation (TENS) for 44 patients with 
demonstrated detrusor overactivity (DO), showing increased mean cystometric 
capacity and mean volume at involuntary detrusor contractions during stimulation [7]. 
Schreiner et al. carried out a placebo controlled, randomized trial of 12 weeks of 
TTNS versus pelvic floor muscular training alone, to treat idiopathic urgency 
incontinence demonstrating significant efficacy of TTNS over placebo [14].   
 
Satisfactory compliance was confirmed with the submission of a compliance diary for 
those patients who completed the therapy. The device was found to be safe as no 
significant adverse effects were noted, although 5 patients experienced some 
discomfort with the stimulation. This may be due to the slow frequency of the 
stimulation which is more noticeable than faster frequency stimulation as used with 
other devices, and also due to possible recruitment of cutaneous afferent nerves which 
does not occur with PTNS. Patients rated the device as easy to use and operate, and 
would recommend the treatment to a friend for use. 
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Fifty-three percent of our patients completing 12-weeks of treatment reported a 
moderate to significant improvement using the GRA scale. This is comparable to the 
improvements seen in a phase 3 multicentric randomized study comparing PTNS 
treatment with sham stimulation (SUmiT study) where 54.5% of the patients in the 
treatment arm reported moderate or marked improvements in bladder symptoms using 
the same GRA scale [1].  
 
 
The preliminary results of this study seem to suggest a benefit in bladder diary 
paramters, OAB scores and LUT symptom related quality of life scores, however this 
exploratory phase 2 study was not designed to evaluate efiacy and therefore 
conclusions cannot be drawn. The improvements observed in both arms of the  study 
would help inform the design of a properly powered study to evaluate efficacy of this 
device.  Unexpectedly, benefits were observed as early as four weeks into the 
treatment, however continued to improve at week 8 and at week 12 of treatment.  
Greater improvements noted in the weekly treatment arm was surprising, and a future 
study should include in the design an evaluation of  different frequencies of treatment 
sessions.   
 
It appeared in our study that neurological patients more often responded to treatment 
(65%) compared to patients with idiopathic OAB (36%).  There were no significant 
differences in tolerability between groups. This supports previous observations of the 
benefits of TNS in patients with neurological disease.  Several studies have already 
demonstrated the efficacy of PTNS in different patient groups with neurological 
disease [15-20].  De Seze et al performed a multicentric study of 70 patients with MS 
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reporting symptoms of OAB using a TENS machine which was applied for 20 
minutes daily and noted by day 30 significant improvements in urgency and 
frequency [8].  Likewise, benefits of TTNS have been demonstrated in patients with 
Parkinson’s disease [20].   
 
Our study was limited by the high attrition rate. There were several reasons for 
patients dropping out including device-related (n=8), perceived lack of improvement 
in OAB symptoms (n=2) and local discomfort (n==5) where the nerve stimulation 
was felt to be unpleasant or too intense. Participants were permitted to adjust the 
strength of stimulation to achieve the balance of a device setting high enough for 
sufficient sensory-motor response and yet not too high where it may become 
unpleasant.   
There are several advantages of transcutaneous TTNS over PTNS because of the 
convenience of home-based neuromodulation, without the need for regular outpatient 
visits.  Using a self-contained skin-adhering device such as the device used in this 
study has the added advantage of permitting ambulation during the treatment, without 
restricting activity of the patient.  As the study lacked a sham arm, a placebo effect 
could not be entirely excluded, especially considering the early benefits in OAB and 
quality of life scores noted in patients receiving weekly treatment.  Whereas a sham 
arm may be possible when studying PTNS [1] it is a challenging prospect in a 
randomized double blinded TTNS study and therefore future studies would need to be 
designed  comparing  TTNS against established treatments.  Furthermore, a future 
study should be designed to compare different stimulation parameters such as pulse 
intensity and frequency, for optimization of stimulation settings [21].  
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The prospects of a portable, non-intrusive, cost-effective, transcutaneous mode of 
stimulation delivery has clear advantages and warrants further investigation for this 




This study demonstrates that the use of a novel non-invasive ambulatory tibial nerve 
stimulation device was both safe and acceptable for patients with high levels of 
compliance. Low frequency stimulation of the tibial nerve at 1 Hz was shown, for the 
first time in a clinical study, to improve storage symptom severity from both quality 
of life questionnaire and 3-day bladder diary data. Further studies are however 
required to evaluate the efficacy and optimal treament frequency of transcutaneous 
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Figure three A and B: Changes in mean ICIQ-OAB scores over the course of 12 
weeks in patients receiving weekly and daily treatment  
 
3A: Change in mean ICIQ-OAB part A scores  
 
 
x-axis: 1: baseline, 2: week-4, 3: week-8, 4:week-12. 
 






x-axis: 1: baseline, 2: week-4, 3: week-8, 4:week-12. 
 
ICIQ-OAB: International Consultation on Incontinence Questionnaire Overactive 
Bladder  
 
Table 1: Results of a customised patient satisfaction survey where results were 




Question Mean score  
The device instructions are easy to 
understand  
6.2 
The device is easy to attach and 
remove  
6 
The device is easy to operate  6 
The device is comfortable to use  5.2 
I have full mobility when I am wearing 
the device  
5.8 
The device improved my symptoms  4.8 
Overall I am satisfied with the device  4.8 
I would recommend the device to a 




 Table 2: Demographic characteristics of responders and non-responders of 34 patients 




 Responders (n=18) Non-Responders  (n=16) 
Mean age (years) 
 
42 (12.6) 48.3 (8.4) 
Mean EDSS  score 
(Neurological patients) 
 
4 (2.5-6) 3.7 (2.5-6) 
Weekly:daily arm (n) 
 
9:9 6:10 
Idiopathic OAB:MS (n) 
 
5:13 9:7 
EDSS: Expanded Disability Status Scale 
MS: Multiple sclerosis  
 
  
Table 3:  Changes in overactive bladder symptoms, quality of life scores and bladder 
diary parameters in patients undergoing 12 weeks of transcutaneous tibial nerve 
stimulation  









part A score 
mean (SD) 
   
Baseline 
 
9.2 (2.2) 9.3 (2.5) 9.1 (1.9) 
Week 4 
 
7.1 (2.9) 7.8 (3.2) 6.9 (2.7) 
Week 8 
 
7.5 (2.6) 8.1 (2.4) 6.7 (2.9) 
Week 12 
 
6.7 (2.5) 7.5 (3.1) 5.9 (1.7) 
ICIQ-OAB 
part B score 
mean (SD) 
 
   
Baseline 
 
29.6 (7.1) 29.6 (8.1) 29.7 (5.9) 
Week 4 
 
25.8 (8.9) 27.8 (9.7) 23.1 (7.6) 
Week 8 
 
25.7 (9.4) 29.5 (7.6) 22.5 (10.1) 
Week 12 
 
22.5 (9.3) 25.6 (9.5) 19.1 (8.5) 
ICIQ-
LUTSqol part 
A score mean 
(SD) 
   
Baseline 
 
48.4 (11.0) 51 (12.8) 44.9 (9.0) 
Week 4 
 
44.2 (13.0) 46.7 (15.8) 40.8 (8.4) 
Week 8 
 
42 (12.7) 46.4 (16.3) 38.3 (8.4) 
Week 12 
 
40.5 (10.6) 44.2 (13.1) 35.9 (8.8) 
ICIQ-    
LUTSqol part 





113.7 (45.4) 130.3 (43.7) 102.1 (40.1) 
Week 4 
 
99.3 (51.1) 111.6 (59.4) 85.6 (38.0) 
Week 8 
 
95.6 (51.7) 114.7 (60.1) 79.3 (41.6) 
Week 12 
 





   
Baseline 
 
11.5 10.8 12.2 
Week 4 
 
10.3 10.2 10.4 
Week 8 
 
10.8 10.2 11.7 
Week 12 
 





   
Baseline 
 
2.5 2.8 2.3 
Week 4 
 
1.6 1.8 1.4 
Week 8 
 
1.9 1.8 2.1 
Week 12 
 




ICIQ-OAB: International Consultation on Incontinence Questionnaire Overactive 
Bladder questionnaire  
ICIQ-LUTSqol: International Consultation on Incontinence Questionnaire Lower 
urinary tract symptoms quality of life questionnaire 
SD: standard deviation 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
